Svas Biosana S p A : Financial statements as at and for the year ended 31 December 2022 approved

PRESS RELEASE

SVAS BIOSANA S.p.A.'S ORDINARY SHAREHOLDERS' MEETING

Financial statements as at and for the year ended 31 December 2022 approved

Allocation of the net profit for the year to reserves approved

Engagement for the statutory audit of the financial statements for the period 2023-2025

assigned

Purchase and disposal of own shares authorised

Somma Vesuviana (Naples), 16 May 2023. Svas Biosana S.p.A., (the "Company"or "SVAS"), a leading operator in the healthcare sector, active in the production and distribution of medical devices for public and private healthcare facilities, listed on Euronext Growth Milan - a multilateral trading system organised and managed by Borsa Italiana S.p.A. dedicated to small and medium-sized enterprises with high growth potential

• announces that its Shareholders met today on first call and approved the financial statements of Svas Biosana S.p.A. as at and for the year ended 31 December 2022 and examined the consolidated financial statements at the same date.

Pursuant to article 106.4 and 5 of Decree law no. 18 of 17 March 2020 , the shareholders participated in the meeting solely through the representative appointed under article 135-undecies of Legislative decree no. 58 dated 24 February 1998 (Consolidated law of finance), specifically Ms. Donatella de Lieto Vollaro, who was also entrusted with proxies/sub-proxies in accordance with article 135-novies of the TUF, by way of derogation from article 135-undecies.4 of the TUF.

Highlights of the Group's financial statements

In 2022, revenues from sales amount to €97.2 million, up 19.9% on 2021

Production revenues amount to €102.3 million, up 25.5% on 2021

EBITDA (gross operating profit), amount to €11.9 million, up 11.7% on 2021

EBIT (operating profit) amount to €6.3 million, up 8.4% on 2021

The net profit for the year amounts to €3.6 million, up 13.0% on 2021

The Net Financial Position (NFP) is cash negative by €21.7 million

Shareholders' equity amounts to €54.5 million

Highlights of the Parent's financial statements

Revenues from sales amount to €55.4 million

Production revenues amount to €60.4 million

EBITDA (gross operating margin) amount to €5.9 million

EBIT (operating profit) amount to €2.2 million

The net profit for the year amounts to €0.8 million

The Net Financial Position (NFP) is cash negative by €16.9 million

Shareholders' equity amounts to €44.8 million

ALLOCATION OF THE NET PROFIT FOR THE YEAR

During their meeting, the Shareholders approved the proposed allocation of the net profit for the year as submitted by the Board of Directors, which envisaged the following:

• €722,800 to the extraordinary reserve
• €38,042 to the legal reserve

ENGAGEMENT FOR THE STATUTORY AUDIT OF THE FINANCIAL STATEMENTS ASSIGNED

The Shareholders' Meeting approved the Board of Directors' proposal, supported by the Board of Statutory Auditors, to engage PricewaterhouseCoopers S.p.A. to perform the statutory audit of the Group's individual and consolidated financial statements for the 2023-2025 period, in accordance with the engagement letter received from said audit company.

PURCHASE AND DISPOSAL OF OWN SHARES AUTHORISED

In their meeting, the Shareholders also decided, at the proposal of the Board of Directors, to authorise the purchase and disposal of own shares, subject to the revocation of the previous authorisation decision dated 19 November 2021 effective from the date of approval of this resolution, for the portion not executed.

Purchases will take place at a unit price which shall not differ by more than 15% from the official stock exchange price of the shares recorded by Borsa Italiana S.p.A. on the trading day preceding each transaction, in compliance with the terms and conditions set forth by the applicable laws and regulations, including EU laws and regulations, and the market practices in force from time to time.

The authorisation is requested to purchase own shares, in one or more instalments, up to a maximum number that, based on Svas Biosana S.p.A. own shares held from time to time by the Company and its subsidiaries, does not exceed, in total, one fifth of the Company's share capital or for a maximum aggregate amount of €1.5 million or any different maximum amount provided for by the law in force at the time.

As of today, the Company holds 216,131 own shares, accounting for 3.8595% of the share capital. The authorisation to purchase was granted for the maximum term (18 months) provided under article 2357.2 of the Italian Civil Code , starting from the date of this decision. Conversely, the disposal of said shares is not subject to time limits in order to enable the Board of Directors to act with maximum flexibility in the interest of the Company.

* * * * * *

The documentation required by the regulations in force relating to today's Shareholders' Meeting will be made available to the public, within the terms of the law, at the Company's registered office, and will be available on the Company's website www.svas.itin the Investor-Relations/Shareholders' Meeting section, as well as on the Borsa Italiana website www.borsaitaliana.it.

This press release can be found at Borsa Italiana, at the Company's registered office, and in the Investor Relations/Financial Press Releases section of the website www.svas.it. Svas Biosana uses the eMarket SDIR system, managed by Teleborsa S.r.l., with registered office at Piazza di Priscilla 4, 00199, Rome (www.emarketstorage.com), to disclose regulated information.

Contacts:

Svas Biosana manufactures and distributes medical devices in Italy and abroad. Founded in 1972 in Somma Vesuviana (NA) by the Perillo family, SVAS is now an international company with a catalogue of approximately 16,000 own and third party brand products, roughly 390 employees, a Research and Development department, 3 production facilities in Italy and subsidiaries in Slovenia, Croatia, Serbia and Bosnia- Herzegovina.

Ticker: ISIN Ordinary Shares: IT0005469264 Ticker: ISIN Warrant SVAS BIOSANA 2021-2024: IT0005469157